Reduction of Phosphorylated Tau during Memantine Treatment of Alzheimer's Disease
2007 (English)In: Dementia and Geriatric Cognitive Disorders, ISSN 1420-8008, E-ISSN 1421-9824, Vol. 24, no 4, 247-252 p.Article in journal (Refereed) Published
Background: Memantine is a moderate affinity N-methyl-D-aspartate receptor antagonist approved for treatment of Alzheimer's disease (AD). In AD, tau is abnormally hyperphosphorylated. However, no significant changes of phosphorylated tau levels in CSF are found at follow-up in studies with AD patients. It has been shown in vitro that memantine reverse induced abnormal hyperphosphorylation of tau in hippocampal neurons of rats. Methods: Eleven AD patients were examined with cognitive tests and interviews of relatives. CSF analyses were performed before starting treatment with memantine as well as after 1 year. Results: A statistically significant reduction of CSF phosphorylated tau at the 1-year follow-up was seen, from median 126 (interquartile range 107-153) to 108 (88-133) ng/l (p = 0.018). No statistically significant differences of total tau or A42 were found. Conclusion: The results may reflect effects of memantine on a key pathological feature in AD in line with previous in vitro findings.
Place, publisher, year, edition, pages
2007. Vol. 24, no 4, 247-252 p.
Alzheimer's disease, Memantine, Phosphorylated tau, Cerebrospinal fluid
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-11724DOI: 10.1159/000107099ISI: 000249536700002PubMedID: 17700020OAI: oai:DiVA.org:uu-11724DiVA: diva2:39493